HER2-positive breast cancer is a molecularly-defined subtype of breast cancer characterized by amplification or overexpression of the ERBB2 (HER2/neu) gene, encoding a receptor tyrosine kinase. HER2 amplification occurs in approximately 15-20% of breast cancers and historically conferred poor prognosis before the advent of HER2-targeted therapies. The development of trastuzumab revolutionized treatment and established HER2+ breast cancer as a paradigm for targeted therapy in solid tumors. Modern treatment includes multiple HER2-targeted agents including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates.
Ask a research question about HER2-Positive Breast Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: HER2-Positive Breast Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-11T02:45:15Z'
description: >-
HER2-positive breast cancer is a molecularly-defined subtype of breast cancer
characterized by amplification or overexpression of the ERBB2 (HER2/neu) gene,
encoding a receptor tyrosine kinase. HER2 amplification occurs in approximately
15-20% of breast cancers and historically conferred poor prognosis before the
advent of HER2-targeted therapies. The development of trastuzumab revolutionized
treatment and established HER2+ breast cancer as a paradigm for targeted therapy
in solid tumors. Modern treatment includes multiple HER2-targeted agents including
monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates.
categories:
- Molecularly-Defined Cancer
- Breast Cancer Subtype
- Solid Tumor
parents:
- breast carcinoma
external_assertions:
- name: CIViC ERBB2 amplification trastuzumab sensitivity assertion
source: CIViC
assertion_type: accepted_assertion
external_id: CIVIC_ASSERTION:2
url: https://civicdb.org/links/assertions/2
description: >-
CIViC accepted assertion that ERBB2 amplification in HER2-receptor positive
breast cancer predicts sensitivity/response to trastuzumab.
notes: >-
01-May-2026 CIViC accepted assertion: molecular_profile="ERBB2
Amplification"; disease="Her2-receptor Positive Breast Cancer";
assertion_type=Predictive; significance=Sensitivity/Response; therapy=Trastuzumab;
AMP category=Tier I - Level A.
evidence:
- reference: CIVIC_ASSERTION:2
reference_title: "ERBB2 Amplification / Her2-receptor Positive Breast Cancer (Predictive Sensitivity/Response)"
supports: SUPPORT
evidence_source: OTHER
snippet: HER2 amplification predicts sensitivity to Trastuzumab
explanation: CIViC records an accepted predictive sensitivity assertion for ERBB2 amplification and trastuzumab in HER2-positive breast cancer.
pathophysiology:
- name: ERBB2 Gene Amplification
description: >-
HER2-positive breast cancer is driven by amplification of the ERBB2 gene on
chromosome 17q12, resulting in overexpression of the HER2 receptor tyrosine
kinase. Gene amplification typically results in 25-50 copies per cell, leading
to massive receptor overexpression on the cell surface.
evidence:
- reference: PMID:40303293
reference_title: "PPARG Activation of Fatty Acid Metabolism Drives Resistance to Anti-HER2 Therapies in HER2-Positive Breast Cancer."
supports: PARTIAL
snippet: HER2-positive breast cancer, which accounts for approximately 15-20% of all breast cancers, is characterized by its aggressive recurrence, metastasis and reduced survival.
explanation: This abstract identifies HER2-positive breast cancer as a distinct, aggressive subtype, supporting the disease definition used here.
- reference: CIVIC_ASSERTION:2
reference_title: "ERBB2 Amplification / Her2-receptor Positive Breast Cancer (Predictive Sensitivity/Response)"
supports: SUPPORT
evidence_source: OTHER
snippet: HER2 amplification defines a clinically relevant subtype of breast cancer.
explanation: CIViC's accepted assertion supports ERBB2/HER2 amplification as the defining molecular feature of HER2-positive breast cancer.
cell_types:
- preferred_term: luminal epithelial cell of mammary gland
term:
id: CL:0002326
label: luminal epithelial cell of mammary gland
biological_processes:
- preferred_term: ERBB2 signaling pathway
modifier: INCREASED
term:
id: GO:0038128
label: ERBB2 signaling pathway
downstream:
- target: Constitutive Receptor Activation
description: Receptor overexpression leads to ligand-independent dimerization and activation
- name: Constitutive Receptor Activation
description: >-
Massive HER2 overexpression promotes spontaneous receptor homodimerization and
heterodimerization with other ERBB family members (EGFR, HER3, HER4) without
ligand binding. This constitutive activation drives downstream signaling cascades
promoting proliferation, survival, and invasion.
biological_processes:
- preferred_term: transmembrane receptor protein tyrosine kinase signaling pathway
modifier: INCREASED
term:
id: GO:0007169
label: cell surface receptor protein tyrosine kinase signaling pathway
downstream:
- target: Downstream Oncogenic Signaling
description: Activated HER2 phosphorylates intracellular substrates
- name: Downstream Oncogenic Signaling
description: >-
Activated HER2 signals through PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways,
promoting cell proliferation, survival, and resistance to apoptosis. HER2-HER3
heterodimers are particularly potent activators of the PI3K pathway.
biological_processes:
- preferred_term: phosphatidylinositol 3-kinase signaling
modifier: INCREASED
term:
id: GO:0043491
label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
- preferred_term: MAPK cascade
modifier: INCREASED
term:
id: GO:0000165
label: MAPK cascade
downstream:
- target: Uncontrolled Proliferation
description: Sustained signaling drives tumor growth
- name: Uncontrolled Proliferation
description: >-
Constitutive HER2 signaling drives continuous cell cycle progression and
resistance to apoptotic signals. HER2+ tumors are typically high grade with
high proliferation indices (high Ki-67).
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
histopathology:
- name: Invasive Ductal Carcinoma
finding_term:
preferred_term: Invasive Breast Carcinoma of No Special Type
term:
id: NCIT:C4194
label: Invasive Breast Carcinoma of No Special Type
frequency: VERY_FREQUENT
description: Invasive ductal carcinoma is the most common type of breast cancer.
evidence:
- reference: PMID:39806949
reference_title: "An Overview of Invasive Ductal Carcinoma (IDC) in Women's Breast Cancer."
supports: PARTIAL
snippet: "Invasive ductal carcinoma (IDC) is the most common type of breast cancer,"
explanation: Abstract states that invasive ductal carcinoma is the most common breast cancer type.
phenotypes:
- category: Neoplastic
name: Breast Carcinoma
frequency: OBLIGATE
diagnostic: true
description: >-
HER2-positive breast cancers are typically invasive ductal carcinomas of
high histologic grade. They often present as palpable masses or are detected
on screening mammography.
phenotype_term:
preferred_term: Breast carcinoma
term:
id: HP:0003002
label: Breast carcinoma
- category: Histopathologic
name: High Grade Tumor
frequency: VERY_FREQUENT
description: >-
HER2+ breast cancers are predominantly high grade (grade 2-3) with high
mitotic rates and nuclear pleomorphism.
phenotype_term:
preferred_term: Neoplasm
term:
id: HP:0002664
label: Neoplasm
- category: Molecular
name: HER2 Overexpression
frequency: OBLIGATE
diagnostic: true
description: >-
Defining feature is HER2 protein overexpression (IHC 3+) or gene amplification
(FISH HER2/CEP17 ratio ≥2.0 or HER2 copy number ≥6). IHC 2+ requires reflex
FISH testing for confirmation.
phenotype_term:
preferred_term: Neoplasm
term:
id: HP:0002664
label: Neoplasm
biochemical:
- name: HER2 Testing (IHC and FISH)
notes: >-
HER2 status is determined by immunohistochemistry (IHC) for protein expression
and/or fluorescence in situ hybridization (FISH) for gene amplification. IHC
scores of 0-1+ are negative, 2+ is equivocal (requires FISH), and 3+ is positive.
FISH positive is defined as HER2/CEP17 ratio ≥2.0 or average HER2 copy number ≥6.
genetic:
- name: ERBB2
association: Somatic Amplification
inheritance:
- name: Somatic
notes: >-
ERBB2 (17q12) encodes the HER2 receptor tyrosine kinase. Amplification occurs
somatically and is not inherited. The amplicon often includes neighboring genes
including GRB7 and TOP2A. Amplification level correlates with HER2 protein
expression and response to HER2-targeted therapy.
evidence:
- reference: PMID:23628726
reference_title: "The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond."
supports: PARTIAL
snippet: "HER2 gene amplification is observed in about 15% of breast cancers."
explanation: "Abstract reports HER2 amplification frequency in breast cancer."
- reference: CIVIC_ASSERTION:2
reference_title: "ERBB2 Amplification / Her2-receptor Positive Breast Cancer (Predictive Sensitivity/Response)"
supports: SUPPORT
evidence_source: OTHER
snippet: HER2 amplification predicts sensitivity to Trastuzumab
explanation: CIViC's accepted assertion supports ERBB2 amplification as the treatment-predictive genetic alteration for trastuzumab response.
- name: PIK3CA
association: Co-occurring Mutations
inheritance:
- name: Somatic
notes: >-
PIK3CA mutations occur in approximately 30% of HER2+ breast cancers and may
confer resistance to HER2-targeted therapy. Testing is recommended for
treatment selection (alpelisib in ER+/HER2+ cases).
treatments:
- name: Trastuzumab
description: >-
Humanized monoclonal antibody targeting the extracellular domain of HER2.
First-line treatment in combination with chemotherapy. Revolutionized
HER2+ breast cancer treatment, converting a poor-prognosis subtype into
one with excellent outcomes.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: trastuzumab
term:
id: CHEBI:231601
label: trastuzumab
evidence:
- reference: CIVIC_ASSERTION:2
reference_title: "ERBB2 Amplification / Her2-receptor Positive Breast Cancer (Predictive Sensitivity/Response)"
supports: SUPPORT
evidence_source: OTHER
snippet: HER2 amplification predicts sensitivity to Trastuzumab
explanation: CIViC's accepted assertion directly supports trastuzumab sensitivity in ERBB2-amplified HER2-positive breast cancer.
- name: Pertuzumab
description: >-
Humanized monoclonal antibody that binds HER2 at a different epitope than
trastuzumab, preventing HER2 dimerization. Used in combination with
trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic
settings.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: pertuzumab
term:
id: NCIT:C38692
label: Pertuzumab
- name: Trastuzumab Deruxtecan (T-DXd)
description: >-
Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I
inhibitor payload. Highly effective in HER2+ metastatic breast cancer after
prior trastuzumab, and also active in HER2-low breast cancer.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: trastuzumab deruxtecan
term:
id: NCIT:C128799
label: Trastuzumab Deruxtecan
- name: Tucatinib
description: >-
Oral HER2-selective tyrosine kinase inhibitor with activity against brain
metastases. Used in combination with trastuzumab and capecitabine in
previously treated HER2+ metastatic breast cancer.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: tucatinib
term:
id: NCIT:C77896
label: Tucatinib
- name: Neratinib
description: >-
Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended
adjuvant therapy after trastuzumab-based treatment and for metastatic
disease in combination with capecitabine.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: neratinib
term:
id: CHEBI:61397
label: neratinib
disease_term:
preferred_term: HER2 positive breast carcinoma
term:
id: MONDO:0006244
label: HER2 positive breast carcinoma
classifications:
icdo_morphology:
classification_value: Adenocarcinoma
harrisons_chapter:
- classification_value: cancer
- classification_value: solid tumor
Disease Pathophysiology Research Report
Target Disease - Disease Name: HER2-Positive Breast Cancer - MONDO ID: MONDO:0007254 (breast carcinoma; HER2-positive is a molecularly defined subtype) - Category: Malignant neoplasm; solid tumor, breast
Pathophysiology description - Key concepts and definitions. HER2-positive breast cancer is driven by amplification/overexpression of ERBB2 (HER2), a receptor tyrosine kinase of the ErbB/EGFR family. HER2 lacks a soluble ligand and signals largely via homo- and heterodimers—particularly HER2/HER3—potently activating PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways that regulate proliferation, survival, metabolism, and invasion (URL: https://doi.org/10.3390/genes15070903, Jul 2024). Quote: “HER2/HER3 heterodimer is highly potent in activating downstream signaling pathways, such as PI3K/AKT and MAPK.” (cheng2024acomprehensivereview pages 5-6) - Dysregulated signaling. HER2 amplification increases receptor density (often to millions of receptors/cell), enhancing ligand-independent dimerization and downstream signaling. Trastuzumab blocks HER2 ECD IV, inhibits HER2–HER3-driven PI3K signaling, and promotes ADCC, highlighting the centrality of PI3K/AKT and MAPK cascades in disease biology (URL: https://doi.org/10.3390/cancers16152635, Jul 2024) (cai2024depictingbiomarkersfor pages 2-4). Reviews consistently identify HER2 amplification/overexpression and HER2 heterodimerization as initiating events that “disrupt the balance between cell proliferation and apoptosis” through PI3K/AKT/mTOR and Ras/Raf/MEK/ERK activation (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 2-4). - Cellular processes. Hyperactive PI3K/AKT enhances survival, cell cycle progression, glucose and lipid metabolism, and EMT/invasion; RAS/MAPK promotes proliferation and transcriptional programs. PI3K/AKT also shapes an immunosuppressive microenvironment (e.g., PD-L1, TAM recruitment), contributing to metastasis and therapeutic resistance (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 2-4, zhong2024thebiologicalroles pages 14-16). - Immune mechanisms. Anti-HER2 mAbs (trastuzumab) exert Fc-mediated effects including ADCC and macrophage ADCP in addition to signaling blockade (URL: https://doi.org/10.3390/cancers16152635, Jul 2024) (cai2024depictingbiomarkersfor pages 2-4). ADCs add cytotoxic payload delivery and, depending on linker/payload, “bystander” killing of neighboring cells (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 1-2). - Clinical phenotype and CNS tropism. HER2-positive disease comprises ~15–25% of breast cancers and is clinically aggressive with a high risk of brain metastases; approximately 25–50% of patients with HER2-positive metastatic breast cancer develop brain metastases during the disease course (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2) (zhong2024thebiologicalroles pages 1-2, zhong2024thebiologicalroles pages 2-4).
1) Core Pathophysiology - Primary pathophysiological mechanisms. HER2 gene amplification/overexpression drives constitutive HER2 signaling, particularly via HER2/HER3 heterodimers, activating PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways that promote proliferation, survival, and invasion (URL: https://doi.org/10.3390/genes15070903, Jul 2024; https://doi.org/10.3390/ijms252413376, Dec 2024) (cheng2024acomprehensivereview pages 5-6, zhong2024thebiologicalroles pages 2-4). - Dysregulated molecular pathways. Central: PI3K/AKT/mTOR (lipid signaling PIP2→PIP3; AKT activation via PDK1 and mTORC2), RAS/RAF/MEK/ERK (MAPK) (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 2-4). Crosstalk with ER signaling in HR+/HER2+ disease enables escape from anti-HER2 therapy (URL: https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/genes15070903, Jul 2024) (zhong2024thebiologicalroles pages 14-16, cheng2024acomprehensivereview pages 5-6). - Cellular processes affected. Cell cycle progression (cyclin/CDK activation), survival and anti-apoptosis (AKT signaling), EMT and invasion (e.g., integrin/FAK/PI3K/AKT; lipid mediators), metabolic rewiring (AKT-driven glucose/lipid metabolism), and microenvironmental immune suppression (TAMs, CAFs) (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 14-16).
2) Key Molecular Players - Genes/Proteins (HGNC): ERBB2/HER2 (HGNC:3430), ERBB3/HER3 (HGNC:3431), EGFR/ERBB1 (HGNC:3236), PIK3CA (HGNC:8975), PTEN (HGNC:9588), AKT1 (HGNC:391), MAPK1 (HGNC:6871), MAPK3 (HGNC:6877), GRB7 (HGNC:4567), ESR1 (HGNC:3467). Mechanistically, trastuzumab blocks HER2 ECD IV and reduces HER3 phosphorylation and PI3K signaling; HER2/HER3 dimers are potent PI3K activators; PIK3CA mutations and PTEN loss increase PI3K output; GRB7 can maintain downstream ERK/AKT signaling and contribute to resistance (URLs: https://doi.org/10.3390/cancers16152635, Jul 2024; https://doi.org/10.3390/genes15070903, Jul 2024; https://doi.org/10.3390/ijms252413376, Dec 2024) (cai2024depictingbiomarkersfor pages 2-4, cheng2024acomprehensivereview pages 5-6, zhong2024thebiologicalroles pages 14-16). - Chemical entities (selected): anti-HER2 mAbs and ADCs (trastuzumab; ado-trastuzumab emtansine/T-DM1; trastuzumab deruxtecan/T-DXd), and TKIs (lapatinib, neratinib, tucatinib, pyrotinib) that variably penetrate the CNS and inhibit HER2/EGFR family kinases (URLs: https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/cancers16152635, Jul 2024) (zhong2024thebiologicalroles pages 1-2, cai2024depictingbiomarkersfor pages 2-4). - Cell types (CL terms): breast carcinoma epithelial cells (CL:0000066-derived), tumor-associated macrophages (CL:0000235), CD8+ T cells (CL:0000625), cancer-associated fibroblasts/fibroblasts (CL:0000057). Microenvironmental TAMs and CAFs promote PI3K/AKT signaling, immunosuppression, and EMT (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 14-16). - Anatomical locations (UBERON): breast (UBERON:0000310), lymph node (UBERON:0000029), brain (UBERON:0000955), bone (UBERON:0001474), liver (UBERON:0002107), lung (UBERON:0002048). High CNS metastasis propensity in HER2+ disease is well documented (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2).
3) Biological Processes (GO annotation) - Signaling: transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169); phosphatidylinositol 3-kinase signaling (GO:0014065); MAPK cascade (GO:0000165/GO:0000187); regulation of ER signaling (cross-talk) (GO:0030520). Activation of PI3K/AKT and MAPK downstream of HER2/HER3 is the central driver (URLs: https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/genes15070903, Jul 2024) (zhong2024thebiologicalroles pages 2-4, cheng2024acomprehensivereview pages 5-6). - Cellular programs: positive regulation of cell proliferation (GO:0008284); epithelial to mesenchymal transition (GO:0001837); regulation of cell cycle (GO:0051726); apoptotic process (GO:0006915); glucose metabolic process (GO:0006006) and lipid metabolic process (GO:0006629) via AKT; immune response/ADCC-related processes (GO:0006955). PI3K/AKT contributes to EMT and immune evasion (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 14-16). - Transport and trafficking: endocytosis and receptor internalization (GO:0006897), vesicle-mediated transport (GO:0016192), lysosomal degradation (GO:0009056 context), relevant for HER2 turnover and ADC processing (URL: https://doi.org/10.3390/genes15070903, Jul 2024) (cheng2024acomprehensivereview pages 5-6).
4) Cellular Components (GO:CC) - Plasma membrane (GO:0005886) and receptor complex at the membrane; early/late endosomes (GO:0005768/GO:0005769) and lysosome (GO:0005764) for receptor downregulation and ADC trafficking; cytosol (GO:0005829) and nucleus (GO:0005634) for downstream signaling transcriptional responses; extracellular region (GO:0005576) for ADC bystander payload diffusion (URLs: https://doi.org/10.3390/genes15070903, Jul 2024; https://doi.org/10.3390/ijms252413376, Dec 2024) (cheng2024acomprehensivereview pages 5-6, zhong2024thebiologicalroles pages 1-2).
5) Disease Progression - Sequence of events. (i) ERBB2 amplification → HER2 overexpression (40–100×; up to ~2 million receptors/cell) enables ligand-independent dimerization (notably with HER3); (ii) acute activation of PI3K/AKT/mTOR and MAPK cascades drives proliferation/survival; (iii) microenvironmental conditioning (TAM/CAF-driven immunosuppression, EMT) promotes invasion and dissemination; (iv) clinical metastasis with high CNS risk, reflecting both tumor-intrinsic biology and limited BBB penetration of large antibodies; (v) therapy-induced selective pressures yield resistance via PI3K/AKT reactivation (PIK3CA, PTEN), HER family rewiring (HER3 upregulation), ER crosstalk, and ADC- or TKI-specific mechanisms (URLs: https://doi.org/10.3390/cancers16152635, Jul 2024; https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/biomedicines13051153, May 2025) (cai2024depictingbiomarkersfor pages 2-4, zhong2024thebiologicalroles pages 2-4, miski2025her2positivebreastcancer—current pages 1-2). - Stages/phases. Early localized disease (HER2-driven proliferation), regional spread (lymph nodes), distant metastasis with tropism for brain/liver/lung/bone; brain metastases are frequent (25–50%) and a major cause of mortality (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2).
6) Phenotypic Manifestations (HP terms) - Breast carcinoma (HP:0100013) with aggressive clinical course (Neoplasm aggressiveness, HP:0025315), high relapse risk without targeted therapy, and frequent brain metastases (HP:0031426) and leptomeningeal disease in advanced cases (HP:0031746). Neurologic symptoms in CNS involvement include headache, seizures, and focal deficits (clinical phenotype aligns with brain metastasis biology) (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2).
Resistance to anti-HER2 therapies (mechanisms and recent insights) - PI3K/AKT pathway alterations. PIK3CA activating mutations and PTEN loss restore downstream signaling and drive resistance to trastuzumab, pertuzumab, TKIs, and ADCs; PI3K/AKT activation also promotes EMT and immune evasion (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 1-2, zhong2024thebiologicalroles pages 2-4, zhong2024thebiologicalroles pages 14-16). - HER family rewiring. Upregulation of HER3 and maintenance of HER2–HER3 signaling sustain PI3K activation under HER2 blockade; ECD alterations and increased HER2 expression can reduce antibody efficacy (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 2-4). - ER crosstalk (HR+/HER2+). Approximately half of HER2+ tumors express ER; bidirectional crosstalk allows ER-driven escape from anti-HER2 therapy, supporting combined endocrine plus anti-HER2 or PI3K/AKT/mTOR blockade (URLs: https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/genes15070903, Jul 2024) (zhong2024thebiologicalroles pages 14-16, cheng2024acomprehensivereview pages 5-6). - ADC-specific resistance. Mechanisms include reduced target antigen/heterogeneity, impaired internalization/trafficking, lysosomal dysfunction, drug efflux, and payload-specific alterations (e.g., TOP1 mutations with DXd). Design features (cleavable linkers, DAR, hydrophilic masking) modulate bystander effects and resistance profiles (URL: https://doi.org/10.3390/molecules30143026, Jul 2025) (li2025recentresearchadvances pages 15-17). - BBB and brain metastasis biology. Large antibodies have poor BBB penetration, permitting CNS relapse even with systemic control; CNS-active TKIs (e.g., tucatinib, neratinib) and potent ADCs (e.g., T-DXd) have improved intracranial activity, changing management of HER2+ brain metastases (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2).
Immune mechanisms and ADC pharmacology - ADCC/ADCP. Trastuzumab engages Fcγ receptors on NK cells and macrophages, mediating ADCC/ADCP and contributing significantly to efficacy; it also reduces HER2/HER3 signaling and can increase PTEN activity via Src inhibition (URL: https://doi.org/10.3390/cancers16152635, Jul 2024) (cai2024depictingbiomarkersfor pages 2-4). - ADC bystander effect and cytotoxicity. Modern ADCs (e.g., T-DXd) use cleavable linkers and membrane-permeable payloads to produce bystander killing, enhancing efficacy in heterogeneous tumors; this property is repeatedly emphasized in recent reviews (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 1-2).
Recent developments and latest research (2023–2024 priority) - Centrality of PI3K/AKT in resistance and therapeutic combinations. 2024 reviews summarize how PI3K/AKT alterations, microenvironmental crosstalk, and ER signaling sustain resistance, motivating rational combinations (e.g., anti-HER2 + endocrine ± PI3K/AKT/mTOR inhibitors) (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 1-2, zhong2024thebiologicalroles pages 14-16). - Updated mechanistic reviews of HER2 biology. 2024 synthesis details HER2 regulation, HER2/HER3 potency, and post-translational control (e.g., ubiquitination, HSP90) relevant to receptor turnover and drug sensitivity (URL: https://doi.org/10.3390/genes15070903, Jul 2024) (cheng2024acomprehensivereview pages 5-6). - Biomarkers of resistance. 2024 review catalogs predictive biomarkers for resistance across mAbs, TKIs, and ADCs, including PIK3CA/PTEN, HER family rewiring, and immune contexture, with treatment implications (URL: https://doi.org/10.3390/cancers16152635, Jul 2024) (cai2024depictingbiomarkersfor pages 1-2, cai2024depictingbiomarkersfor pages 2-4).
Current applications and real-world implementations - Standard-of-care anti-HER2 backbones (trastuzumab + pertuzumab + taxane) and use of TKIs and ADCs in advanced settings remain central, with evolving adoption of CNS-active regimens for brain metastases (neratinib, tucatinib, T-DM1, T-DXd) (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2).
Expert opinions and analysis - Reviews converge on: (i) HER2/HER3-driven PI3K/AKT as the dominant oncogenic axis; (ii) resistance via PI3K/AKT reactivation, HER3 upregulation, ER crosstalk, and ADC/TKI-specific mechanisms; (iii) need for rational combinations and CNS-active strategies due to BBB constraints and high BrM incidence (URLs: https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/cancers16152635, Jul 2024; https://doi.org/10.3390/genes15070903, Jul 2024) (zhong2024thebiologicalroles pages 1-2, zhong2024thebiologicalroles pages 2-4, cai2024depictingbiomarkersfor pages 1-2, zhong2024thebiologicalroles pages 14-16, cheng2024acomprehensivereview pages 5-6, cai2024depictingbiomarkersfor pages 2-4).
Relevant statistics and data - Incidence: HER2-positive constitutes ~15–25% of breast cancers (2024 reviews) (URLs: https://doi.org/10.3390/ijms252413376, Dec 2024; https://doi.org/10.3390/cancers16152635, Jul 2024) (zhong2024thebiologicalroles pages 1-2, cai2024depictingbiomarkersfor pages 1-2). - Receptor abundance: HER2 amplification can yield ~25–50 copies of ERBB2 and ~40–100-fold increase in receptor number (≈2 million receptors/cell) (URL: https://doi.org/10.3390/cancers16152635, Jul 2024) (cai2024depictingbiomarkersfor pages 2-4). - CNS risk: 25–50% of HER2-positive metastatic breast cancer patients develop brain metastases, a leading contributor to mortality (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2).
Ontology-linked annotations - Genes/Proteins (HGNC): ERBB2 (HGNC:3430), ERBB3 (HGNC:3431), PIK3CA (HGNC:8975), PTEN (HGNC:9588), AKT1 (HGNC:391), MAPK1 (HGNC:6871), MAPK3 (HGNC:6877), ESR1 (HGNC:3467), GRB7 (HGNC:4567). Evidence: signaling and resistance roles as above (zhong2024thebiologicalroles pages 1-2, zhong2024thebiologicalroles pages 2-4, zhong2024thebiologicalroles pages 14-16, cheng2024acomprehensivereview pages 5-6, cai2024depictingbiomarkersfor pages 2-4). - Biological Processes (GO): GO:0007169; GO:0014065; GO:0000165/GO:0000187; GO:0008284; GO:0001837; GO:0006915; GO:0006006; GO:0006629; GO:0006955; GO:0016192 (zhong2024thebiologicalroles pages 2-4, zhong2024thebiologicalroles pages 14-16, cheng2024acomprehensivereview pages 5-6). - Cellular Components (GO:CC): GO:0005886; GO:0005768/GO:0005769; GO:0005764; GO:0005829; GO:0005634; GO:0005576 (cheng2024acomprehensivereview pages 5-6, zhong2024thebiologicalroles pages 1-2). - Phenotype associations (HP): HP:0100013; HP:0025315; HP:0031426; HP:0031746 (miski2025her2positivebreastcancer—current pages 1-2). - Cell types (CL): CL:0000066; CL:0000235; CL:0000625; CL:0000057 (zhong2024thebiologicalroles pages 14-16). - Anatomical locations (UBERON): UBERON:0000310; UBERON:0000029; UBERON:0000955; UBERON:0001474; UBERON:0002107; UBERON:0002048 (miski2025her2positivebreastcancer—current pages 1-2). - Chemical entities (CHEBI; selected metabolites central to signaling): PIP2 (CHEBI:18348), PIP3 (CHEBI:16618). Therapeutics are referenced by name due to inconsistent CHEBI coverage for biologics/ADCs (zhong2024thebiologicalroles pages 2-4).
Direct supporting quotations - “HER2/HER3 heterodimer is highly potent in activating downstream signaling pathways, such as PI3K/AKT and MAPK.” (URL: https://doi.org/10.3390/genes15070903, Jul 2024) (cheng2024acomprehensivereview pages 5-6) - “HER2-targeted therapies work by preventing receptor dimerization … and by inhibiting kinase activity … The PI3K/AKT pathway is frequently altered … and plays a central role in proliferation and drug resistance.” (URL: https://doi.org/10.3390/ijms252413376, Dec 2024) (zhong2024thebiologicalroles pages 1-2) - “Trastuzumab … binds HER2 ECD IV … and [induces] ADCC … [and] inhibits PI3K/AKT signaling … by promoting PTEN activity (via Src inhibition).” (URL: https://doi.org/10.3390/cancers16152635, Jul 2024) (cai2024depictingbiomarkersfor pages 2-4) - “Approximately 25–50% of patients with HER2-positive breast cancer experience brain metastases.” (URL: https://doi.org/10.3390/biomedicines13051153, May 2025) (miski2025her2positivebreastcancer—current pages 1-2)
Evidence items with URLs and dates - Zhong et al., 2024, Int J Mol Sci (Dec 2024). PI3K/AKT centrality in resistance; mechanisms and combinations. URL: https://doi.org/10.3390/ijms252413376 (zhong2024thebiologicalroles pages 1-2, zhong2024thebiologicalroles pages 2-4, zhong2024thebiologicalroles pages 14-16) - Cheng, 2024, Genes (Jul 2024). HER2 biology and HER2/HER3 potency and regulation. URL: https://doi.org/10.3390/genes15070903 (cheng2024acomprehensivereview pages 5-6) - Cai et al., 2024, Cancers (Jul 2024). Biomarkers of resistance; clinical agents; mechanistic roles for ADCC/PI3K. URL: https://doi.org/10.3390/cancers16152635 (cai2024depictingbiomarkersfor pages 1-2, cai2024depictingbiomarkersfor pages 2-4) - Miski et al., 2025, Biomedicines (May 2025). CNS tropism; 25–50% BrM; therapeutic landscape including CNS-active agents. URL: https://doi.org/10.3390/biomedicines13051153 (miski2025her2positivebreastcancer—current pages 1-2) - Li et al., 2025, Molecules (Jul 2025). ADC design features and resistance modes; TOP1 payload context. URL: https://doi.org/10.3390/molecules30143026 (li2025recentresearchadvances pages 15-17)
Notes on scope and limitations - Where possible, we prioritized 2023–2024 sources; several 2024 reviews directly address HER2 signaling and resistance. Some quantitative epidemiology (CNS risk) is from a 2025 synthesis but aligns with longstanding observations. Mechanistic details are consistent across multiple 2024 reviews. Future work can add primary PMIDs for individual molecular events (e.g., specific PIK3CA/PTEN mutations and clinical correlations) and incorporate guideline updates for HER2-low as new evidence is fully appraised.
References
(cheng2024acomprehensivereview pages 5-6): Xiaoqing Cheng. A comprehensive review of her2 in cancer biology and therapeutics. Genes, Jul 2024. URL: https://doi.org/10.3390/genes15070903, doi:10.3390/genes15070903. This article has 191 citations and is from a poor quality or predatory journal.
(cai2024depictingbiomarkersfor pages 2-4): Alvan Cai, Yuan Chen, Lily S. Wang, John K. Cusick, and Yihui Shi. Depicting biomarkers for her2-inhibitor resistance: implication for therapy in her2-positive breast cancer. Cancers, 16:2635, Jul 2024. URL: https://doi.org/10.3390/cancers16152635, doi:10.3390/cancers16152635. This article has 9 citations and is from a poor quality or predatory journal.
(zhong2024thebiologicalroles pages 2-4): Hanyi Zhong, Ziling Zhou, Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang, and Zheng Wang. The biological roles and clinical applications of the pi3k/akt pathway in targeted therapy resistance in her2-positive breast cancer: a comprehensive review. International Journal of Molecular Sciences, 25:13376, Dec 2024. URL: https://doi.org/10.3390/ijms252413376, doi:10.3390/ijms252413376. This article has 26 citations and is from a poor quality or predatory journal.
(zhong2024thebiologicalroles pages 14-16): Hanyi Zhong, Ziling Zhou, Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang, and Zheng Wang. The biological roles and clinical applications of the pi3k/akt pathway in targeted therapy resistance in her2-positive breast cancer: a comprehensive review. International Journal of Molecular Sciences, 25:13376, Dec 2024. URL: https://doi.org/10.3390/ijms252413376, doi:10.3390/ijms252413376. This article has 26 citations and is from a poor quality or predatory journal.
(zhong2024thebiologicalroles pages 1-2): Hanyi Zhong, Ziling Zhou, Han Wang, Ruo Wang, Kunwei Shen, Renhong Huang, and Zheng Wang. The biological roles and clinical applications of the pi3k/akt pathway in targeted therapy resistance in her2-positive breast cancer: a comprehensive review. International Journal of Molecular Sciences, 25:13376, Dec 2024. URL: https://doi.org/10.3390/ijms252413376, doi:10.3390/ijms252413376. This article has 26 citations and is from a poor quality or predatory journal.
(miski2025her2positivebreastcancer—current pages 1-2): Hanna Miski, Kamila Krupa, Michał Piotr Budzik, Andrzej Deptała, and Anna Badowska-Kozakiewicz. Her2-positive breast cancer—current treatment management and new therapeutic methods for brain metastasis. Biomedicines, 13:1153, May 2025. URL: https://doi.org/10.3390/biomedicines13051153, doi:10.3390/biomedicines13051153. This article has 1 citations and is from a poor quality or predatory journal.
(li2025recentresearchadvances pages 15-17): Junmin Li, Xue Li, Ruixin Fu, Yakun Fang, Chunmei Zhang, Bingbing Ma, Yanan Ding, CX Shi, and Qingfeng Zhou. Recent research advances in her2-positive breast cancer concerning targeted therapy drugs. Molecules, Jul 2025. URL: https://doi.org/10.3390/molecules30143026, doi:10.3390/molecules30143026. This article has 3 citations and is from a poor quality or predatory journal.
(cai2024depictingbiomarkersfor pages 1-2): Alvan Cai, Yuan Chen, Lily S. Wang, John K. Cusick, and Yihui Shi. Depicting biomarkers for her2-inhibitor resistance: implication for therapy in her2-positive breast cancer. Cancers, 16:2635, Jul 2024. URL: https://doi.org/10.3390/cancers16152635, doi:10.3390/cancers16152635. This article has 9 citations and is from a poor quality or predatory journal.